Author

Xin Hu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

VCP‐Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple‐Negative Breast Cancer

A previously unrecognized VCP‐LMF2‐HMGCS1 regulatory axis that drives TNBC progression and chemoresistance is unveiled, and lipase maturation factor 2 is identified as a promising therapeutic target for this recalcitrant disease.

Qian Zhao, Lisa Andriani, Yin-Ling Zhang et al. · Advancement of science · 0 citations

Review Open access Sep 2026

Landscape of cancer genomics and precision oncology in Japan, South Korea, China, and Australia

Summary Precision oncology has expanded rapidly across the Asia–Pacific region, yet implementation remains heterogeneous because of differences in health-system organisation, reimbursement, molecular tumour board infrastructure, workforce capacity, and data integration. This structured narrative review with expert cons...

H. Bando, H. Okayama, Yoon Jung Chang et al. · The Lancet Regional Health -... · 1 citation

Open access Sep 2026

Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metasta...

S. Shi, Miao-Yan Wei, N. Du et al. · Cancer Cell · 1 citation